Kwang Dong 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   3 Trials   143 News 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vyleesi (bremelanotide) / Palatin Technologies
NCT04179734: Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

Completed
4
40
Europe
Bremelanotide, Placebo
Imperial College Healthcare NHS Trust, AMAG Pharmaceuticals, Inc.
Hypoactive Sexual Desire Disorder
10/20
10/20
NCT06867835: Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

Not yet recruiting
4
10
NA
Vyleesi (Bremelanotide Injection)
Cosette Pharmaceuticals, Inc.
Lactating Mother
07/25
10/25
KD-BMT-301, NCT04943068: A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Completed
3
193
RoW
Bremelanotide, Placebo
Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
05/23
05/23
ACTRN12615001059550: A Within-Subject Single Dose Trial on the Effects of Bremelanotide on Social Cognition and Behaviour

Recruiting
2
60
 
University of Sydney, Simons Foundations
Autism Spectrum Disorder
 
 
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
BMT-801, NCT06565611: A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity

Active, not recruiting
2
108
US
bremelanotide, tirzepatide
Palatin Technologies, Inc
Obesity
02/25
03/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vyleesi (bremelanotide) / Palatin Technologies
NCT04179734: Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder

Completed
4
40
Europe
Bremelanotide, Placebo
Imperial College Healthcare NHS Trust, AMAG Pharmaceuticals, Inc.
Hypoactive Sexual Desire Disorder
10/20
10/20
NCT06867835: Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast Milk

Not yet recruiting
4
10
NA
Vyleesi (Bremelanotide Injection)
Cosette Pharmaceuticals, Inc.
Lactating Mother
07/25
10/25
KD-BMT-301, NCT04943068: A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

Completed
3
193
RoW
Bremelanotide, Placebo
Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
05/23
05/23
ACTRN12615001059550: A Within-Subject Single Dose Trial on the Effects of Bremelanotide on Social Cognition and Behaviour

Recruiting
2
60
 
University of Sydney, Simons Foundations
Autism Spectrum Disorder
 
 
BREAKOUT, NCT05709444: A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease

Completed
2
16
US
Bremelanotide, Bremelanotide acetate, RAAS inhibition therapy, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
Palatin Technologies, Inc
Kidney Disease
04/24
04/24
BMT-801, NCT06565611: A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity

Active, not recruiting
2
108
US
bremelanotide, tirzepatide
Palatin Technologies, Inc
Obesity
02/25
03/25

Download Options